Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic…
Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib…
Read More...
Read More...